MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
preferred stock
$1,600K
Net cash provided by
financing activities
$1,519K
Canceled cashflow
$81K
Net decrease in cash
-$28K
Canceled cashflow
$1,519K
Accounts payable
$16K
Payments on behalf of
related party
$81K
Net cash used in
operating activities
-$1,547K
Canceled cashflow
$16K
Net loss
-$1,252K
Other accrued
liabilities
-$236K
Prepaid expenses and
other current assets
$75K
Back
Back
Cash Flow
source: myfinsight.com
TITAN PHARMACEUTICALS INC (TTNP)
TITAN PHARMACEUTICALS INC (TTNP)